AnaptysBio (NASDAQ:ANAB) Hits New 1-Year High at $41.11

AnaptysBio, Inc. (NASDAQ:ANAB)’s share price reached a new 52-week high during trading on Wednesday . The company traded as high as $41.11 and last traded at $40.56, with a volume of 366230 shares. The stock had previously closed at $33.33.

Analyst Upgrades and Downgrades

ANAB has been the subject of several analyst reports. SVB Leerink initiated coverage on shares of AnaptysBio in a report on Tuesday, April 16th. They set an “outperform” rating and a $47.00 price target for the company. Leerink Partnrs restated an “outperform” rating on shares of AnaptysBio in a report on Tuesday, April 16th. JPMorgan Chase & Co. increased their price target on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Wedbush reissued an “outperform” rating and issued a $34.00 price objective on shares of AnaptysBio in a research note on Friday, May 10th. Finally, HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, AnaptysBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.56.

AnaptysBio Trading Up 18.0 %

The firm has a market capitalization of $1.07 billion, a P/E ratio of -6.63 and a beta of -0.25. The stock’s 50-day simple moving average is $28.97 and its 200-day simple moving average is $25.43.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The business had revenue of $10.97 million during the quarter, compared to the consensus estimate of $25.85 million. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. On average, equities research analysts expect that AnaptysBio, Inc. will post -6.32 EPS for the current year.

Insider Buying and Selling

In other news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. Following the transaction, the insider now owns 11,618 shares of the company’s stock, valued at approximately $406,630. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other AnaptysBio news, Director Hollings Renton sold 10,000 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $30.64, for a total transaction of $306,400.00. Following the sale, the director now owns 1,950 shares of the company’s stock, valued at approximately $59,748. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total value of $52,500.00. Following the sale, the insider now owns 11,618 shares in the company, valued at approximately $406,630. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,900 shares of company stock valued at $484,824. 33.70% of the stock is owned by company insiders.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ensign Peak Advisors Inc boosted its stake in AnaptysBio by 74.4% in the 2nd quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock worth $1,898,000 after purchasing an additional 32,313 shares during the period. Renaissance Technologies LLC boosted its position in shares of AnaptysBio by 52.4% in the second quarter. Renaissance Technologies LLC now owns 152,702 shares of the biotechnology company’s stock valued at $3,827,000 after acquiring an additional 52,502 shares during the period. Headlands Technologies LLC grew its stake in AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 2,900 shares in the last quarter. TD Asset Management Inc increased its holdings in AnaptysBio by 67.3% during the 2nd quarter. TD Asset Management Inc now owns 37,800 shares of the biotechnology company’s stock worth $947,000 after acquiring an additional 15,200 shares during the period. Finally, Rhumbline Advisers increased its holdings in AnaptysBio by 1.8% during the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock worth $745,000 after acquiring an additional 525 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.